Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP4 | P49662 | 1/20 | 0.52 |
| ▸ | CASP5 | P51878 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026435 | 0.88 | CHRNB2 (0.85) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| SCHEMBL9346879 | 0.84 | SIGMAR1 (0.67) | KDM4EALDH1A1CHRNA7 | |
| SCHEMBL7194677 | 0.84 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| SCHEMBL8306431 | 0.83 | CHRNB2 (0.72) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| SCHEMBL15800693 | 0.83 | CHRNB2 (0.77) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL2985111 | 0.83 | CHRNB2 (0.66) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| SCHEMBL4166707 | 0.83 | CHRNB2 (0.66) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL2980328 | 0.82 | CHRNB2 (0.70) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| Bromide SCHEMBL4166152 | 0.81 | CHRNB2 (0.64) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| N-(3-Pyridylmethyl)Pyrrolidine SCHEMBL1538320 | 0.81 | CHRNB2 (1.00) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | CHRNB2 4380/4885CHRNA4 3116/4885KDM4E 1661/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | CHRNB2 4510/4885CHRNA4 3595/4885KDM4E 920/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | CHRNB2 4380/4885CHRNA4 3116/4885KDM4E 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.